# CJC-1295 Frequently Asked Questions | Online Edition > Direct cited answers to 25 frequently asked CJC-1295 questions — mechanism, DAC vs no-DAC, half-life, dosage, side effects, regulatory status, ipamorelin pairing. Twenty-five questions a careful reader asks about CJC-1295 — direct cited answers from the published record. ## The questions Below: every CJC-1295 question this site receives a meaningful search-volume signal on, with a direct cited answer from the published literature. ### What is CJC-1295? A synthetic 30-amino-acid analog of growth hormone-releasing hormone (GHRH 1-29) with four amino-acid substitutions that resist enzymatic degradation; the DAC variant attaches a maleimidopropionic-acid linker that binds serum albumin and extends plasma half-life from minutes to roughly 8 days [1][3]. ### What does CJC-1295 do to your body? Binds GHRH receptors on anterior pituitary somatotrophs and stimulates endogenous growth-hormone release; downstream hepatic IGF-1 elevation follows and persists for days to weeks under sustained dosing of the DAC variant [3][4]. ### How does CJC-1295 work? It acts as a long-acting GHRH agonist. The DAC moiety extends serum half-life from minutes (native GHRH) to roughly 8 days, sustaining pulsatile GH release across the dosing interval [3][4]. The four amino-acid substitutions to the GHRH 1-29 backbone confer proteolytic stability [2]. ### What is the difference between CJC-1295 with DAC and without DAC? CJC-1295 DAC carries a drug-affinity-complex linker that binds albumin (half-life 5.8-8.1 days). Without DAC ([modified GRF 1-29](/research#modified-grf-1-29)) the half-life is ~30 minutes, producing a pulsatile rather than sustained GH elevation [3][10]. ### What is the half-life of CJC-1295? Approximately 5.8-8.1 days for CJC-1295-DAC in published pharmacokinetic studies of healthy adults [3]. Approximately 30 minutes for the non-DAC modified GRF 1-29 variant [10]. The order-of-magnitude difference is the DAC linker's contribution. ### How many days a week do you inject CJC-1295? DAC version: typically reported as once or twice weekly in protocols because of the long half-life [3][9]. Non-DAC modified GRF 1-29: typically reported as daily or pre-bedtime injections to mimic native pulsatility [10]. Frequency follows half-life in the published research. ### What are the side effects of CJC-1295? Most-reported in the literature and clinical observations: flushing, mild headache, injection-site redness, water retention, transient numbness or tingling, and occasional dizziness [3][15]. No serious adverse reactions were reported at the tested doses in the two completed Phase 1 studies [3][4]. ### What are the negative side effects of CJC-1295? Sustained elevation of GH and IGF-1 raises theoretical concerns around insulin resistance, fluid retention, and proliferative effects [15]. One 2006 Phase 2 trial (NCT00267527) was halted after a participant died of a fatal myocardial infarction; the trial sponsor judged the event most likely unrelated to the peptide but discontinued development [5][9]. ### What are the bad side effects of CJC-1295 and Ipamorelin? The stacked profile reported in the observational research literature is similar to CJC-1295 alone, with the addition of ipamorelin-related transient hunger and occasional mild GI symptoms [12]. Long-term safety data for the paired protocol is absent — no completed Phase 2 or Phase 3 trial has formally evaluated it [12]. ### Is CJC-1295 safe? No regulatory approval as a therapeutic in humans [16]. Short-term safety in two Phase 1 studies in healthy adults was reported as acceptable at the tested doses [3][4]. Long-term human safety is undefined. One fatal adverse event in early industry trials halted development [5]. ### Does CJC-1295 raise testosterone? No direct testosterone-stimulating effect has been demonstrated. CJC-1295 acts on the GH/IGF-1 axis, not on the hypothalamic-pituitary-gonadal axis [3]. Any reported gonadal effects in the broader research-peptide literature would be indirect consequences of altered GH/IGF-1 signaling, not direct HPG-axis stimulation. ### Does CJC-1295 mess with hormones? It directly elevates GH and IGF-1 under sustained dosing of the DAC variant [3]. Indirect effects on insulin sensitivity (transient insulin resistance is reported in the GH-excess literature) and possible fluid and sodium balance via GH-axis activation are documented [15]. No direct HPG-axis effect [3]. ### What is CJC-1295 ipamorelin good for? The pair is studied as a complementary GH-stimulation strategy: CJC-1295 (GHRH analog) raises baseline GH release via the GHRH receptor while ipamorelin (selective ghrelin/GHS-R1a agonist) adds a pulsatile spike without affecting cortisol or prolactin [12]. Two distinct receptors, additive GH-release pathways. ### How long do CJC-1295 and ipamorelin take to work? IGF-1 elevation is detectable within days in pharmacokinetic studies of CJC-1295-DAC [3]. Subjective changes reported in observational user surveys typically appear at 4-8 weeks, but the observational record is not placebo-controlled and effect sizes are not quantified in completed Phase 2 or Phase 3 trials. ### How long does it take to see results from CJC-1295? Pharmacological markers (serum GH, IGF-1) elevate within days under DAC-variant dosing [3]. Body-composition changes in observational user-reported protocols are typically described at 8-12 weeks but have not been measured in completed placebo-controlled Phase 2 or Phase 3 trials of CJC-1295 [9]. ### How do you reconstitute CJC-1295 with ipamorelin (5mg)? Typical reconstitution methodology described in clinical-pharmacy SOPs: aseptic addition of bacteriostatic water to the lyophilized vial, gentle swirling without shaking, refrigerated storage at 2-8 °C [14]. Specific volumes vary by vial concentration; no peer-reviewed human reconstitution standard has been published for either compound. ### What is CJC-1295 DAC? Drug Affinity Complex variant: a maleimidopropionic-acid linker covalently binds the free thiol of Cys34 on serum albumin, sheltering the peptide from enzymatic degradation and extending half-life to roughly 8 days [1]. The 67 kDa peptide-albumin complex is too large for glomerular filtration. ### What is modified GRF 1-29? The non-DAC version of CJC-1295: the same four amino-acid substitutions to GHRH 1-29, but without the albumin-binding linker. Plasma half-life ~30 minutes producing pulsatile GH release rather than the sustained pattern of CJC-1295-DAC [10]. ### How much CJC-1295 should I take? This site does not recommend doses for humans. In published research: the DAC variant was studied in Phase 1 ascending-dose work at 60-250 µg/kg subcutaneous, with weekly or biweekly cohorts; the non-DAC variant has been described in research protocols at roughly 100 µg subcutaneous before bed [3][9][10]. ### What is the difference between CJC-1295 and ipamorelin? CJC-1295 is a GHRH analog acting on the GHRH receptor. Ipamorelin is a selective ghrelin/GHS-R1a receptor agonist [12]. Different receptors. Complementary, additive GH-release pathways. The pair is studied together because the two activations are receptor-distinct rather than redundant. ### Is CJC-1295 FDA approved? No. Not approved by the FDA for any therapeutic indication [16]. Industry development was halted after a 2006 fatal adverse event in a Phase 2 trial [5]. The FDA removed CJC-1295 and ipamorelin acetate from Section 503A Category 2 effective 27 September 2024 [16]. The World Anti-Doping Agency prohibits the compound in and out of competition [7]. ### Celebrity associations: separating signal from noise Celebrity-associated peptide-use queries surface frequently in search results but are anecdotal and not supported by published clinical research. This online edition sticks to the peer-reviewed CJC-1295 record — what the trials measured, what the half-life data shows, what the regulatory record says. ### GH-axis peptides and body composition Sustained GH and IGF-1 elevation is associated with reductions in visceral adipose tissue in the broader GH-axis research record [15][17]. Tesamorelin — a structurally distinct GHRH 1-44 analog and the only FDA-approved GHRH analog — reduces visceral adipose tissue by ~15% over 26 weeks in HIV-associated lipodystrophy [17]. Direct comparable efficacy data for CJC-1295 in placebo-controlled trials does not exist. ### Combinations cautioned against in the literature Stacking multiple GHRH analogs, or pairing CJC-1295 with exogenous insulin or anabolic agents, amplifies GH/IGF-1 elevation and is cautioned against in published clinical reviews on additive insulin-resistance and proliferative-risk grounds [15]. Conservative receptor-pathway-counting is the principle the literature supports. ### How is CJC-1295 administered? Subcutaneous injection in all published clinical studies [13]. Oral formulations are not bioavailable — gastric proteases cleave the GHRH backbone before absorption. Intranasal delivery has been explored experimentally for related GHRH analogs but is not validated for CJC-1295 in peer-reviewed clinical literature [13]. ## References [1] Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. https://pubmed.ncbi.nlm.nih.gov/15817669/ [2] Coy DH, et al. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men. Journal of Clinical Endocrinology and Metabolism. 1994. https://pubmed.ncbi.nlm.nih.gov/7962295/ [3] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/ [4] Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792-4797. https://pubmed.ncbi.nlm.nih.gov/17018654/ [5] aidsmap editorial team. Lipodystrophy study halted after patient death (news report on ConjuChem CJC-1295 Phase 2 trial NCT00267527). aidsmap (NAM Publications). 2006. https://www.aidsmap.com/news/jul-2006/lipodystrophy-study-halted-after-patient-death [7] World Anti-Doping Agency. The Prohibited List - Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. WADA Prohibited List. 2024. https://www.wada-ama.org/en/prohibited-list [9] ConjuChem Biotechnologies. A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity (NCT00267527). ClinicalTrials.gov. 2005. https://clinicaltrials.gov/study/NCT00267527 [10] Wikipedia editors (citing primary literature on D-Ala2 substitution kinetics). Modified GRF (1-29) - chemical and pharmacological description. 2024. https://en.wikipedia.org/wiki/Modified_GRF_(1-29) [12] Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. https://academic.oup.com/ejendo/article-abstract/139/5/552/6748390 [13] Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295 (route-of-administration record). Journal of Clinical Endocrinology and Metabolism. 2006. https://pubmed.ncbi.nlm.nih.gov/16352683/ [14] ConjuChem Biotechnologies (legacy product documentation, summarized in regulatory filings). Modified GRF (1-29) and CJC-1295 handling — research-use product literature. FDA Docket FDA-2024-N-4777-0002 attachment 7. 2024. https://downloads.regulations.gov/FDA-2024-N-4777-0002/attachment_7.pdf [15] Vijayakumar A, et al. The fascinating interplay between growth hormone, insulin-like growth factor-1, and insulin. Endocrinology and Metabolism (Korea). 2024. https://www.e-enm.org/journal/view.php?doi=10.3803%2FEnM.2024.101 [16] FDA. Section 503A Category 2 removal of CJC-1295 and ipamorelin acetate, effective 27 September 2024. FDA Federal Register / Docket FDA-2024-N-4777. 2024. https://downloads.regulations.gov/FDA-2024-N-4777-0002/attachment_7.pdf [17] Traynor K. FDA approves tesamorelin for HIV-related lipodystrophy. American Journal of Health-System Pharmacy. 2010;67(24):2082. https://academic.oup.com/ajhp/article/67/24/2082/5129928 --- An online journal-supplement reading of the CJC-1295 research record — neo-grotesque on cool white, cobalt-ruled, citation-explicit, and not a vendor, a clinic, or a prescription.